Sanofi Cans Agreement With Kaléo Following Auvi-Q Recalls

French drug giant Sanofi will terminate its licensing agreement with Auvi-Q developer kaléo later this year, returning U.S. and Canadian rights to the epinephrine injection to the company.

The decision follows an October voluntary recall of all marketed Auvi-Q over potentially inaccurate dosage delivery, which may include failure to deliver the drug. Sanofi said it will complete the return and reimbursement process associated with the recall.